Molecular monitoring of major BCR-ABL1 isoform p210 by qPCR reveals differential response to tyrosine kinase inhibitors in accelerated phase CML: a case series

被引：0
|
作者：
Altahan, R. [1 ]
Alsohaibani, L. [1 ]
Khoja, O. T. [1 ]
Zaidi, S. [1 ]
Alghamdi, M. [1 ]
Pukhta, I. A. [1 ]
Tashkandi, S. [1 ]
Zada, Peer A. A. [1 ]
机构：
[1] King Fahad Med City, Riyadh, Saudi Arabia
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P513
引用
收藏
页码：149 / 150
页数：2
相关论文
共 29 条
  • [1] BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Press, Richard D.
    Kamel-Reid, Suzanne
    Ang, Daphne
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 565 - 576
  • [2] Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series
    Rafei, Hind
    Jabbour, Elias Joseph
    Kantarjian, Hagop
    Sinicrope, Kaylyn D.
    Kamiya-Matsuoka, Carlos
    Mehta, Rohtesh S.
    Daver, Naval G.
    Kadia, Tapan M.
    Naqvi, Kiran
    Cortes, Jorge
    Konopleva, Marina
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3292 - 3295
  • [3] Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination
    Bocchia, Monica
    Defina, Marzia
    Aprile, Lara
    Ippoliti, Micaela
    Crupi, Rosaria
    Rondoni, Michela
    Gozzetti, Alessandro
    Lauria, Francesco
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (10) : 600 - 603
  • [4] Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
    Monica Bocchia
    Marzia Defina
    Lara Aprile
    Micaela Ippoliti
    Rosaria Crupi
    Michela Rondoni
    Alessandro Gozzetti
    Francesco Lauria
    Nature Reviews Clinical Oncology, 2010, 7 : 600 - 603
  • [5] Differential in Vitro Sensitivity of BCR::ABL1 Kinase Domain Mutations to Tyrosine Kinase Inhibitors Depending on the p190 or p210 Background
    Lucini, Chantal
    Sponseiler, Isabella
    Senkiv, Julia
    Bandian, Anna-Maria
    Lion, Thomas
    BLOOD, 2024, 144 : 2829 - 2830
  • [6] EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Noh, H.
    Choi, S. -Y.
    Song, H. -Y.
    Kim, S. -H.
    Jung, S. Y.
    Yang, S.
    Lee, W. -S.
    Kim, H. -J.
    Kong, J. H.
    Kim, H.
    Do, Y. R.
    Kwak, J. -Y.
    Oh, S.
    Kim, S. H.
    Kim, J. -A.
    Zang, D. Y.
    Mun, Y. -C.
    Won, Y. -W.
    Lee, S. -E.
    Kim, D. -W.
    Lee, J.
    HAEMATOLOGICA, 2017, 102 : 76 - 76
  • [7] BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
    Pennisi, Maria Stella
    Stella, Stefania
    Vitale, Silvia Rita
    Puma, Adriana
    Di Gregorio, Sandra
    Romano, Chiara
    Tirro, Elena
    Massimino, Michele
    Antolino, Agostino
    Siragusa, Sergio
    Mannina, Donato
    Impera, Stefana
    Musolino, Caterina
    Mineo, Giuseppe
    Martino, Bruno
    Zammit, Valentina
    Di Raimondo, Francesco
    Manzella, Livia
    Stagno, Fabio
    Vigneri, Paolo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [8] PATTERNS OF CHANGE OF THE INHIBITORS OF THE TYROSINE KINASE BCR-ABL1 IN PATIENTS WITH CML IN CHRONIC PHASE IN THE ROUTINE CLINICAL PRACTICE SIMPLICITY STUDY
    Perez Encinas, M.
    Goldberg, S. L.
    Michallet, M.
    Hehlmann, R.
    Zyczynski, T.
    Foreman, A.
    Calimlim, B.
    Paquette, R.
    Simonsson, B.
    Gambacorti Passerini, C.
    Cortes, J.
    Zagorska, A.
    Rong, Y.
    Mauro, M.
    HAEMATOLOGICA, 2017, 102 : 285 - 285
  • [9] Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group
    Itonaga, Hidehiro
    Tsushima, Hideki
    Imanishi, Daisuke
    Hata, Tomoko
    Doi, Yuko
    Mori, Sayaka
    Sasaki, Daisuke
    Hasegawa, Hiroo
    Matsuo, Emi
    Nakashima, Jun
    Kato, Takeharu
    Horai, Makiko
    Taguchi, Masataka
    Matsuo, Masatoshi
    Taniguchi, Hiroaki
    Makiyama, Junnya
    Sato, Shinya
    Horio, Kensuke
    Ando, Koji
    Moriwaki, Yuji
    Sawayama, Yasushi
    Ogawa, Daisuke
    Yamasaki, Reishi
    Takasaki, Yumi
    Imaizumi, Yoshitaka
    Taguchi, Jun
    Kawaguchi, Yasuhisa
    Yoshida, Shinichiro
    Joh, Tatsuro
    Moriuchi, Yukiyoshi
    Nonaka, Hiroaki
    Soda, Hisashi
    Fukushima, Takuya
    Nagai, Kazuhiro
    Kamihira, Shimeru
    Tomonaga, Masao
    Yanagihara, Katsunori
    Miyazaki, Yasushi
    LEUKEMIA RESEARCH, 2014, 38 (01) : 76 - 83
  • [10] F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib
    Oyekunle, Anthony A.
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Soverini, Simona
    Baccarani, Michele
    LEUKEMIA RESEARCH, 2011, 35 (07) : E118 - E120
123